Safety & Pharmacovigilance Writing Fact Sheet Safety & Pharmacovigilance Writing Expertly delivering Safety & Pharmacovigilance Writing services, including Aggregate Safety Reports, Risk Management Plans, and…CertaraFebruary 27, 2026
Blog Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…CertaraFebruary 26, 2026
Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance Press Release Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth…CertaraFebruary 26, 2026
Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD) Guide Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD) Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…CertaraFebruary 13, 2026
EMA Policy 0070 Submission Readiness Checklist Guide EMA Policy 0070 Submission Readiness Checklist Use this EMA Policy 0070 Submission Checklist to prepare compliant clinical data packages, manage anonymization…CertaraFebruary 12, 2026
Pediatric Drug Development: From “Wild West” to Model-Informed Confidence Blog Pediatric Drug Development: From “Wild West” to Model-Informed Confidence Model-informed drug development and precision dosing are transforming pediatric programs, from regulatory planning to Bayesian…CertaraFebruary 11, 2026
Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants Publication Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…CertaraFebruary 2, 2026
Opinion: To Accelerate Rare Disease Progress, Take a Sandbox Approach Press Coverage Opinion: To Accelerate Rare Disease Progress, Take a Sandbox Approach Explore how a collaborative “sandbox” approach—combining flexible regulation, data modeling, and stakeholder engagement—can transform rare…CertaraJanuary 30, 2026
Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients Publication Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…CertaraJanuary 22, 2026